Reneo Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
OKUR$3.39+6.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
(In thousands, except share data)
| Additional · AccumulatedOther · Total | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | |||||||
| Shares · Amount · Capital · Income (Loss) · Deficit · Equity | |||||||
| Balances, December 31, 2023 | 33,420,808 | $3 | $307,073 | $8 | $(218,474) | $88,610 | |
| Stock based compensation | — | — | 1,078 | — | — | 1,078 | |
| Other comprehensive loss | — | — | — | (20) | — | (20) | |
| Net loss | — | — | — | — | (8,426) | (8,426) | |
| Balances, March 31, 2024 | 33,420,808 | $3 | $308,151 | $(12) | $(226,900) | $81,242 | |
| Stock based compensation | — | — | 989 | — | — | 989 | |
| Other comprehensive loss | — | — | — | (1) | (1) | ||
| Net loss | — | — | — | — | (5,361) | (5,361) | |
| Balances, June 30, 2024 | 33,420,808 | $3 | $309,140 | $(13) | $(232,261) | $76,869 | |
Consolidated Statements of Changes in Stockholders’ Equity
(In thousands, except share data)
| Additional · AccumulatedOther · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | ||||||||
| Shares · Amount · Capital · (Loss) Income · Deficit · Equity | ||||||||
| Balances, December 31, 2022 | 24,699,553 | $3 | $236,693 | $(43) | $(136,683) | $99,970 | ||
| Stock based compensation | — | — | 1,157 | — | — | 1,157 | ||
| Issuance of common stock in connection with at-the-market facility, net of issuance costs | 407,877 | — | 1,009 | — | — | 1,009 | ||
| Other comprehensive income | — | — | — | 55 | — | 55 | ||
| Net loss | — | — | — | — | (15,107) | (15,107) | ||
| Balances, March 31, 2023 | 25,107,430 | $3 | $238,859 | $12 | $(151,790) | $87,084 | ||
| Issuance of common stock in public offering, net of offering costs | 7,906,250 | — | 58,862 | — | — | 58,862 | ||
| Issuance of common stock in private placement, net of offering costs | 625,000 | 4,667 | 4,667 | |||||
| Stock based compensation | — | — | 1,207 | — | — | 1,207 | ||
| Issuance of common stock in connection with equity plans | 162,108 | 282 | 282 | |||||
| Other comprehensive loss | — | — | — | (43) | — | (43) | ||
| Net loss | — | — | — | — | (19,531) | (19,531) | ||
| Balances, June 30, 2023 | 33,800,788 | $3 | $303,877 | $(31) | $(171,321) | $132,528 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.